BioTime Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
5,495.50
29,486.90
42,982.00
22,715.00
38,175.00
31,087
Total Accounts Receivable
1,115.20
1,419.80
1,645.00
1,157.00
3,046.00
3,719
Inventories
178.70
266.00
-
-
-
-
Other Current Assets
1,049.60
1,122.30
2,610.00
1,777.00
1,402.00
1,552
Total Current Assets
7,839.00
32,295.10
47,237.00
25,649.00
42,623.00
36,358
Net Property, Plant & Equipment
2,997.70
2,857.80
7,539.00
5,529.00
5,533.00
5,835
Total Investments and Advances
-
-
4,671.00
100,039.00
117,167.00
56,303
Intangible Assets
46,208.10
38,848.40
33,592.00
10,206.00
6,900.00
3,125
Other Assets
685.00
899.60
1,621.00
1,149.00
1,018.00
39
Total Assets
57,729.80
74,900.90
94,660.00
142,572.00
173,241.00
101,660
ST Debt & Current Portion LT Debt
-
117.70
133.00
1,134.00
364.00
Accounts Payable
3,888.00
2,296.60
2,798.00
1,593.00
938.00
Other Current Liabilities
3,070.00
4,714.90
9,531.00
6,123.00
5,577.00
Total Current Liabilities
6,957.90
7,129.30
12,462.00
8,850.00
6,879.00
Long-Term Debt
-
31.30
570.00
1,462.00
150.00
Deferred Taxes
8,277.50
4,514.40
-
-
-
Other Liabilities
232.00
503.20
5,181.00
1,752.00
1,949.00
Total Liabilities
15,467.40
12,178.10
18,213.00
12,064.00
8,978.00
Common Equity (Total)
14,800.80
32,956.00
25,816.00
117,928.00
162,641.00
Total Shareholders' Equity
14,800.80
36,456.00
25,816.00
117,928.00
162,641.00
Total Equity
42,262.30
62,722.80
76,447.00
130,508.00
164,263.00
Liabilities & Shareholders' Equity
57,729.80
74,900.90
94,660.00
142,572.00
173,241.00
Accumulated Minority Interest
27,461.60
26,266.80
50,631.00
12,580.00
1,622.00
Preferred Stock (Carrying Value)
-
3,500.00
-
-
-

About BioTime

View Profile
Address
1010 Atlantic Avenue
Alameda California 94501
United States
Employees -
Website http://www.biotimeinc.com
Updated 07/08/2019
BioTime, Inc. is a clinical-stage biotechnology company, which deals with degenerative diseases. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies.